الفهرس Only 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
The clinical significance of Tissue Inhibitors of metalloproteinase -1 and -2 in serum of patients with nonalcoholic fatty liver disease. Non alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and its incidence is rising worldwide. NAFLD refers to a wide spectrum of liver disease ranging from simple fatty liver (NAFL), to nonalcoholic steatohepatitis (NASH), to cirrhosis. Patients with NASH are at risk for progressive liver disease, emphasizing the clinical importance of developing non-invasive biomarkers for NASH and NASH related fibrosis. Tissue inhibitors of metalloproteinase-1 and -2 (TIMP -1 and -2) were found to be reliable markers for NASH and NASH related fibrosis and are closely linked to the proinflammatory status . In this study we assess the serum level of these two biomarkers in patients with NAFLD. The purpose of this study is to examine the performance of new biomarkers (TIMP -1 and TIMP -2) for NAFL and NASH with a combination of clinical and laboratory variables. This model seems to represent a reliable noninvasive tool in patients with fatty liver disease. 90 subjects were classified into 3 groups: 1) Obese patients with normal liver function (NAFL, n = 30). Obese patients with elevated liver functions (NASH, n = 30). 3) Non obese control group (n = 30). All subjects underwent full medical history, physical examination, body mass index (BMI), fasting blood sugar (FBS), 2 hours postprandial (2HPP), lipid profile, Serum alanine transaminase (ALT), aspartate transaminase (AST), gamma GT levels, alkaline phosphatase (ALP), abdominal ultrasound. Serum TIMP -1 and -2 levels were measured using ELISA. Seven of our patients had liver biopsy